Short Versus Extended Duration of Triple Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients Requiring Oral Anticoagulation: A Retrospective Single‐Center Study
Catheterization and Cardiovascular Interventions · 2026-08 · 108 (2) · 548-553
DOI: 10.1002/ccd.70667 ↗At a glance
Beobachtungsstudie in Catheterization and Cardiovascular Interventions, published online on 2026-05-31. Written by Krishna Prasad Kurpad and 7 co-authors. Institution: Division of Cardiology, Carle Foundation Hospital, Urbana, Illinois, USA. Major MEDLINE topics: Percutaneous Coronary Intervention, Anticoagulants, Fibrinolytic Agents, Platelet Aggregation Inhibitors. 21 references. The full text is freely available in PubMed Central.
Abstract (original language)
Background
Balancing ischemic and bleeding risks in patients undergoing percutaneous coronary intervention (PCI) who require anticoagulation remains a clinical challenge. While dual antithrombotic therapy (DAT) with a P2Y12 inhibitor and an oral anticoagulant reduces long‐term bleeding risk, the optimal duration of triple antithrombotic therapy (TAT) in the immediate post‐procedural phase is uncertain.
Aims
We aimed to evaluate clinical outcomes of short‐duration ({7 days) of TAT to extended‐duration (≥ 7 days) of triple therapy following PCI.
Methods
We conducted a retrospective observational study of 172 patients who underwent PCI. Of these, 109 received TAT for < 7 days, and 63 received TAT for ≥ 7 but < 28 days. The primary outcome was a composite endpoint of cardiovascular mortality, myocardial infarction, target lesion revascularization, and definite or probable stent thrombosis at 1 year. Secondary outcomes were gastrointestinal bleeding (BARC > 3) and intracranial hemorrhage.
Results
There were no statistically significant differences between the two groups in composite outcome (cardiovascular mortality, myocardial infarction, target vessel revascularization, or stent thrombosis at 1 year). Similarly, rates of major bleeding events did not differ significantly between the groups.
Conclusion
Early de‐escalation of TAT (within 7 days) demonstrated similar clinical outcomes to longer durations (< 7 days). Larger randomized controlled trials are warranted to further validate these findings.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Cardiology, Carle Foundation Hospital, Urbana, Illinois, USA.
- CICOM/University of Illinois Urbana Champaign, Champaign, Illinois, USA.
- Department of Internal Medicine, Carle Foundation Hospital, Urbana, Illinois, USA.
- Loyola University, Illinois, Chicago, Illinois, USA.
Cite
APA
Kurpad, K. P., Vorla, M., Bin-Farooq, T., Mehta, R., Adoni, N., Kanakadandi, U. B., Moussa, I. D., & Mehta, S. S. (2026). Short Versus Extended Duration of Triple Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients Requiring Oral Anticoagulation: A Retrospective Single‐Center Study. Catheterization and Cardiovascular Interventions, 108(2), 548-553. https://doi.org/10.1002/ccd.70667
Vancouver
Kurpad KP, Vorla M, Bin-Farooq T, Mehta R, Adoni N, Kanakadandi UB, et al. Short Versus Extended Duration of Triple Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients Requiring Oral Anticoagulation: A Retrospective Single‐Center Study. Catheterization and Cardiovascular Interventions. 2026;108(2):548-553. doi:10.1002/ccd.70667
BibTeX
@article{Kurpad2026,
author = {Kurpad, Krishna Prasad and Vorla, Mounica and Bin-Farooq, Talha and Mehta, Roma and Adoni, Naveed and Kanakadandi, Uday B and Moussa, Issam D and Mehta, Sanjay S},
title = {Short Versus Extended Duration of Triple Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients Requiring Oral Anticoagulation: A Retrospective Single‐Center Study},
journal = {Catheterization and Cardiovascular Interventions},
year = {2026},
volume = {108},
number = {2},
pages = {548--553},
doi = {10.1002/ccd.70667}
}
EUVIMED